Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients.
This report concerns 347 patients with primary hydatidiform moles studied during the first 6 years (1966-1972) of operation of the Southeastern Regional Trophoblastic Disease Center. Aside from a decreased incidence, molar pregnancy in the United States follows a pattern similar to that elsewhere in the world. Abnormal bleeding is the key to early diagnosis, and the frequent use of sensitive HCG assays is the key to proper followup. Twenty percent of patients with hydatidiform moles can be expected to develop subsequent malignant sequelae. Bilateral ovarian enlargement and/or a large-for-dates- uterus should alert the physician to a greater potential for this outcome. Spontaneous elimination of HCG from the circulation following moler pregnancy, as indicated by sensitive assay, would predict a benign postmolar course; no patient in the current series who once achieved undetectable levels of HCG developed malignant trophoblastic disease.
D000028:Abortion, Induced; D000293:Adolescent; D000818:Animals; D001789:Blood Group Antigens; D006063:Chorionic Gonadotropin / Q000652:urine; D003475:Curettage; D004106:Dilatation; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D006828:Hydatidiform Mole / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D008423:Maternal Age; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009362:Neoplasm Metastasis; D009657:North Carolina; D010053:Ovary / Q000473:pathology; D010298:Parity; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011863:Radioimmunoassay; D012075:Remission, Spontaneous; D014599:Uterus / Q000473:pathology
D001789:Blood Group Antigens; D006063:Chorionic Gonadotropin; D008727:Methotrexate